Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Analysts are now discussing an updated €8 price target for Innate Pharma, while the fair value estimate sits at €6.10 with no change to the underlying model. This shift is being framed around what both bullish and bearish voices see in the 2026 catalyst cluster, including funding needs and how upcoming oncology readouts could influence sentiment. As you read on, you will see how these moving pieces fit together and what to watch as the story develops.
Stay updated as the Fair Value for Innate Pharma shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Innate Pharma.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
BTIG assumed coverage of Innate Pharma with a Buy rating and an $8 price target, framing 2026 as a "crucial catalyst stretch" that could reshape how the pipeline is valued.
-
BTIG highlights three oncology assets with key 2026 events, including monalizumab PACIFIC-9 topline data and IPH4502 Phase 1 readout, which some investors may view as multiple shots on goal rather than a single binary event.
-
The firm also points to potential Phase 3 initiation for lacutamab, contingent on financing, which keeps a later stage asset in focus for investors who are comfortable with clinical and funding execution risk.
🐻 Bearish Takeaways
-
BTIG explicitly ties lacutamab's Phase 3 start to financing, which may remind investors that external capital needs could influence dilution, deal terms, and the timing of clinical progress.
-
The clustering of monalizumab, IPH4502, and lacutamab milestones in 2026 concentrates execution and clinical risk into a relatively tight window, which some investors may see as increasing uncertainty around valuation and sentiment swings.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
How This Changes the Fair Value For Innate Pharma
-
Fair Value: €6.10, unchanged with no adjustment to the underlying estimate.
-
Revenue Growth: revised from 45.10% to 50.46% in the model.
-
Net Profit Margin: held at 35.40%, with only a minimal rounding difference.
-
P/E Ratio: future P/E reduced from 49.99x to 44.88x on projected earnings.
-
Discount Rate: moved from 6.78% to 6.81% as the required return input.
Never Miss an Update: Follow The Narrative
Narratives connect a company's real world story to a financial forecast and fair value, so you can see how clinical, funding, and partnership updates feed into the numbers. They refresh over time as new information comes in, giving you a living view of the thesis.
Head over to the Simply Wall St Community and follow the Narrative on Innate Pharma to stay up to date on:
-
How lacutamab's FDA breakthrough therapy status, potential Phase 3 preparation, and partner discussions shape expectations for its commercial path.
-
Progress across the ANKET platform, including IPH65 and the Nectin 4 ADC IPH45, and what early trial enrollment and dosing updates mean for future options in cancer and autoimmune indications.
-
Key risks around crowded non Hodgkin lymphoma markets, partner dependence, trial terminations such as IPH6401 in multiple myeloma, and the reliance on tax credits and collaborations while expenses stay ahead of current revenues.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IPH.PA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
